• 1. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes

Comprehensive Overview of (1R)-1-(m-tolyl)ethanamine;hydrochloride (CAS No. 1167414-88-1)

(1R)-1-(m-tolyl)ethanamine;hydrochloride (CAS No. 1167414-88-1) is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, also known as (R)-α-methyl-m-toluidine hydrochloride, is a derivative of toluene and features an amino group attached to a chiral carbon center. The presence of the chiral center imparts distinct enantiomeric properties, making it a valuable intermediate in the synthesis of various pharmaceuticals and fine chemicals.

The chemical structure of (1R)-1-(m-tolyl)ethanamine;hydrochloride consists of a benzene ring with a methyl group at the meta position, an ethylamine side chain, and a hydrochloride salt. The chiral center at the α-position of the ethylamine group is crucial for its biological activity and selectivity. This compound can be synthesized through various methods, including asymmetric synthesis and resolution techniques, ensuring high enantiomeric purity.

Recent studies have highlighted the potential of (1R)-1-(m-tolyl)ethanamine;hydrochloride in the development of novel drugs. For instance, a 2022 study published in the Journal of Medicinal Chemistry explored its use as a lead compound for designing inhibitors of specific enzymes involved in neurodegenerative diseases. The researchers found that derivatives of this compound exhibited potent inhibitory activity against key enzymes, suggesting its potential as a therapeutic agent.

In addition to its role in drug discovery, (1R)-1-(m-tolyl)ethanamine;hydrochloride has been investigated for its pharmacological properties. A 2023 study in the Bioorganic & Medicinal Chemistry Letters reported that this compound demonstrated significant anti-inflammatory effects in vitro and in vivo models. The study suggested that the compound's mechanism of action involves modulating cytokine production and reducing oxidative stress, making it a promising candidate for treating inflammatory conditions.

The stability and solubility of (1R)-1-(m-tolyl)ethanamine;hydrochloride are important factors to consider in its application. It is generally stable under standard laboratory conditions but may require specific storage conditions to maintain its integrity over extended periods. The compound is soluble in common organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO), which facilitates its use in various chemical reactions and biological assays.

Safety and toxicity profiles are critical aspects of any pharmaceutical compound. Preliminary toxicological studies have indicated that (1R)-1-(m-tolyl)ethanamine;hydrochloride exhibits low toxicity at therapeutic doses. However, further research is necessary to fully understand its long-term effects and potential side effects. Researchers recommend conducting comprehensive preclinical studies to ensure its safety before advancing to clinical trials.

The synthetic pathways for producing (1R)-1-(m-tolyl)ethanamine;hydrochloride have been optimized to achieve high yields and enantiomeric purity. One common method involves the asymmetric reduction of an appropriate ketone precursor using chiral catalysts or biocatalysts. Another approach involves the resolution of racemic mixtures using chiral resolving agents or chromatographic techniques. These methods ensure that the final product meets the stringent quality standards required for pharmaceutical applications.

In conclusion, (1R)-1-(m-tolyl)ethanamine;hydrochloride (CAS No. 1167414-88-1) is a versatile chiral compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for developing novel therapeutics targeting various diseases. Ongoing research continues to explore new applications and improve our understanding of this compound's properties, paving the way for future advancements in drug discovery and development.

• 17279-30-0(Benzenemethanamine, a-methyl-, hydrochloride (1:1), (aS)-)
• 147116-33-4(1-(4-Ethylphenyl)ethanamine hydrochloride)
• 212968-67-7((1S)-1-(4-ethylphenyl)ethan-1-amine)
• 737713-28-9((1R)-1-(3,5-dimethylphenyl)ethan-1-amine)
• 5267-34-5(Benzhydrylamine hydrochloride)
• 138457-18-8((1S)-1-(3-methylphenyl)ethan-1-amine)
• 138457-19-9((1R)-1-(3-methylphenyl)ethan-1-amine)
• 292068-37-2((1R)-1-(4-ethylphenyl)ethan-1-amine)
• 13437-79-1(Benzenemethanamine, a-methyl-, hydrochloride)
• 2627-86-3((S)-alpha-phenylethylamine)